Aviance Capital Partners LLC Grows Stock Position in Johnson & Johnson (NYSE:JNJ)

Aviance Capital Partners LLC grew its position in Johnson & Johnson (NYSE:JNJ) by 63.3% during the 1st quarter, HoldingsChannel.com reports. The fund owned 37,818 shares of the company’s stock after buying an additional 14,663 shares during the quarter. Johnson & Johnson makes up about 0.9% of Aviance Capital Partners LLC’s portfolio, making the stock its 24th largest holding. Aviance Capital Partners LLC’s holdings in Johnson & Johnson were worth $5,982,000 as of its most recent SEC filing.

A number of other institutional investors have also recently added to or reduced their stakes in the stock. Mirador Capital Partners LP lifted its position in Johnson & Johnson by 4.2% during the first quarter. Mirador Capital Partners LP now owns 20,508 shares of the company’s stock worth $3,244,000 after buying an additional 833 shares in the last quarter. SteelPeak Wealth LLC lifted its position in Johnson & Johnson by 11.5% during the first quarter. SteelPeak Wealth LLC now owns 58,409 shares of the company’s stock worth $9,240,000 after buying an additional 6,045 shares in the last quarter. Breakwater Capital Group lifted its position in Johnson & Johnson by 13.0% during the first quarter. Breakwater Capital Group now owns 7,818 shares of the company’s stock worth $1,237,000 after buying an additional 899 shares in the last quarter. Clarity Wealth Advisors LLC lifted its position in Johnson & Johnson by 4.2% during the first quarter. Clarity Wealth Advisors LLC now owns 23,938 shares of the company’s stock worth $3,787,000 after buying an additional 969 shares in the last quarter. Finally, AMI Investment Management Inc. increased its stake in Johnson & Johnson by 3.8% during the first quarter. AMI Investment Management Inc. now owns 22,018 shares of the company’s stock worth $3,483,000 after acquiring an additional 810 shares during the last quarter. Hedge funds and other institutional investors own 69.55% of the company’s stock.

Analysts Set New Price Targets

Several research firms have issued reports on JNJ. Bank of America cut their target price on Johnson & Johnson from $180.00 to $170.00 and set a “neutral” rating for the company in a research note on Wednesday, April 17th. Morgan Stanley cut their target price on Johnson & Johnson from $168.00 to $167.00 and set an “equal weight” rating for the company in a research note on Wednesday, April 17th. Royal Bank of Canada reissued an “outperform” rating and set a $175.00 target price on shares of Johnson & Johnson in a research note on Monday, June 17th. Cantor Fitzgerald reissued an “overweight” rating and set a $215.00 target price on shares of Johnson & Johnson in a research note on Monday. Finally, StockNews.com raised Johnson & Johnson from a “buy” rating to a “strong-buy” rating in a research note on Sunday. Eight equities research analysts have rated the stock with a hold rating, five have given a buy rating and one has issued a strong buy rating to the stock. Based on data from MarketBeat.com, Johnson & Johnson has a consensus rating of “Moderate Buy” and a consensus price target of $174.07.

Johnson & Johnson Trading Down 0.3 %

NYSE:JNJ opened at $146.03 on Wednesday. The company has a current ratio of 1.17, a quick ratio of 0.94 and a debt-to-equity ratio of 0.36. The stock has a fifty day moving average price of $148.09 and a 200 day moving average price of $153.97. Johnson & Johnson has a 12-month low of $143.13 and a 12-month high of $175.97. The firm has a market cap of $351.45 billion, a PE ratio of 9.10, a price-to-earnings-growth ratio of 2.43 and a beta of 0.52.

Johnson & Johnson (NYSE:JNJ) last released its earnings results on Tuesday, April 16th. The company reported $2.71 earnings per share (EPS) for the quarter, topping the consensus estimate of $2.64 by $0.07. Johnson & Johnson had a return on equity of 36.70% and a net margin of 45.26%. The company had revenue of $21.38 billion for the quarter, compared to analysts’ expectations of $21.39 billion. During the same quarter in the previous year, the firm posted $2.68 EPS. The firm’s quarterly revenue was up 2.3% on a year-over-year basis. Sell-side analysts anticipate that Johnson & Johnson will post 10.62 earnings per share for the current fiscal year.

Johnson & Johnson Increases Dividend

The company also recently disclosed a quarterly dividend, which was paid on Tuesday, June 4th. Investors of record on Tuesday, May 21st were paid a $1.24 dividend. This is an increase from Johnson & Johnson’s previous quarterly dividend of $1.19. This represents a $4.96 annualized dividend and a yield of 3.40%. The ex-dividend date was Monday, May 20th. Johnson & Johnson’s dividend payout ratio (DPR) is presently 30.92%.

Johnson & Johnson Profile

Johnson & Johnson, together with its subsidiaries, researches, develops, manufactures, and sells various products in the healthcare field worldwide. The company's Innovative Medicine segment offers products for various therapeutic areas, such as immunology, including rheumatoid arthritis, psoriatic arthritis, inflammatory bowel disease, and psoriasis; infectious diseases comprising HIV/AIDS; neuroscience, consisting of mood disorders, neurodegenerative disorders, and schizophrenia; oncology, such as prostate cancer, hematologic malignancies, lung cancer, and bladder cancer; cardiovascular and metabolism, including thrombosis, diabetes, and macular degeneration; and pulmonary hypertension comprising pulmonary arterial hypertension through retailers, wholesalers, distributors, hospitals, and healthcare professionals for prescription use.